221 related articles for article (PubMed ID: 33046576)
21. HIPEC in advanced epithelial ovarian cancer: why is there controversy?
Vermorken JB; van Dam P; Brand A
Curr Opin Oncol; 2020 Sep; 32(5):451-458. PubMed ID: 32675595
[TBL] [Abstract][Full Text] [Related]
22. Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020).
Farrell R; Burling M; Lee YC; Pather S; Robledo K; Mercieca-Bebber R; Stockler M;
J Gynecol Oncol; 2022 Jan; 33(1):e1. PubMed ID: 34783204
[TBL] [Abstract][Full Text] [Related]
23. Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
Morton M; Chambers LM; Costales AB; Chichura A; Gruner M; Horowitz MP; Rose PG; Yao M; Debernardo R; Michener C
Gynecol Oncol; 2021 Jan; 160(1):45-50. PubMed ID: 33067001
[TBL] [Abstract][Full Text] [Related]
24. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chambers LM; Yao M; Morton M; Gruner M; Chichura A; Horowitz M; Costales AB; Rose PG; Michener CM; Debernardo R
Gynecol Oncol; 2021 May; 161(2):389-395. PubMed ID: 33551202
[TBL] [Abstract][Full Text] [Related]
25. Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial.
Koole SN; van Lieshout C; van Driel WJ; van Schagen E; Sikorska K; Kieffer JM; Schagen van Leeuwen JH; Schreuder HWR; Hermans RH; de Hingh IH; van der Velden J; Arts HJ; Massuger LFAG; Aalbers AG; Verwaal VJ; Van de Vijver KK; Aaronson NK; van Tinteren H; Sonke GS; van Harten WH; Retèl VP
J Clin Oncol; 2019 Aug; 37(23):2041-2050. PubMed ID: 31251694
[TBL] [Abstract][Full Text] [Related]
26. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer.
Cascales-Campos PA; Gil J; Gil E; Feliciangeli E; González-Gil A; Parrilla JJ; Parrilla P
Ann Surg Oncol; 2014 Jul; 21(7):2383-9. PubMed ID: 24599409
[TBL] [Abstract][Full Text] [Related]
27. A Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy in Primary Advanced Ovarian Cancer: The First Reported Pilot Experience from Saudi Arabia.
Abu-Zaid A; Alomar O; Alsabban M; Salem H; Al-Badawi IA
Gulf J Oncolog; 2020 Sep; 1(34):19-25. PubMed ID: 33431358
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery.
Kim JS; Liang MI; Prendergast EN; Alldredge J; Datta A; Hurteau JA; Kirschner CV; Rodriguez G; Vogel TJ; Brooks RA; Cass I; Cohen JG; Penner KR; Wang CE; Diaz Moore ES
Int J Gynecol Cancer; 2019 Sep; 29(7):1156-1163. PubMed ID: 31352365
[TBL] [Abstract][Full Text] [Related]
29. Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer.
Mikkelsen MS; Christiansen T; Petersen LK; Blaakaer J; Iversen LH
J Surg Oncol; 2019 Sep; 120(3):550-557. PubMed ID: 31267569
[TBL] [Abstract][Full Text] [Related]
30. The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study.
Manzanedo I; Pereira F; Serrano Á; Pérez-Viejo E; Martínez-Torres B; Carrión L; Calzas J
Clin Transl Oncol; 2019 Oct; 21(10):1357-1363. PubMed ID: 30788835
[TBL] [Abstract][Full Text] [Related]
31. Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C/IV ovarian cancer. Is there any difference?
Cascales-Campos P; López-López V; Gil J; Arévalo-Pérez J; Nieto A; Barceló F; Gil E; Parrilla P
Surg Oncol; 2016 Sep; 25(3):164-70. PubMed ID: 27566018
[TBL] [Abstract][Full Text] [Related]
32. Cytoreduction and HIPEC after neoadjuvant chemotherapy in stage IIIC-IV ovarian cancer. Critical analysis in elderly patients.
Cascales-Campos P; Gil J; Gil E; Feliciangeli E; López V; Gonzalez AG; Ruiz-Pardo J; Nieto A; Parrilla P
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():88-93. PubMed ID: 24965986
[TBL] [Abstract][Full Text] [Related]
33. Hyperthermic intraperitoneal chemotherapy in interval debulking surgery for advanced epithelial ovarian cancer: A single-center, real-life experience.
Ghirardi V; Ronsini C; Trozzi R; Di Ilio C; Di Giorgio A; Cianci S; Draisci G; Scambia G; Fagotti A
Cancer; 2020 Dec; 126(24):5256-5262. PubMed ID: 32931024
[TBL] [Abstract][Full Text] [Related]
34. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II).
Koemans WJ; van der Kaaij RT; Boot H; Buffart T; Veenhof AAFA; Hartemink KJ; Grootscholten C; Snaebjornsson P; Retel VP; van Tinteren H; Vanhoutvin S; van der Noort V; Houwink A; Hahn C; Huitema ADR; Lahaye M; Los M; van den Barselaar P; Imhof O; Aalbers A; van Dam GM; van Etten B; Wijnhoven BPL; Luyer MDP; Boerma D; van Sandick JW
BMC Cancer; 2019 May; 19(1):420. PubMed ID: 31060544
[TBL] [Abstract][Full Text] [Related]
35. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
[TBL] [Abstract][Full Text] [Related]
36. Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.
Zivanovic O; Chi DS; Zhou Q; Iasonos A; Konner JA; Makker V; Grisham RN; Brown AK; Nerenstone S; Diaz JP; Schroeder ED; Langstraat CL; Paroder V; Lakhman Y; Soldan K; Su K; Gardner GJ; Andikyan V; Guo J; Jewell EL; Long Roche K; Troso-Sandoval T; Lichtman SM; Moukarzel LA; Dessources K; Abu-Rustum NR; Aghajanian C; Tew WP; Beumer J; Sonoda Y; O'Cearbhaill RE
J Clin Oncol; 2021 Aug; 39(23):2594-2604. PubMed ID: 34019431
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
Ansaloni L; Agnoletti V; Amadori A; Catena F; Cavaliere D; Coccolini F; De Iaco P; Di Battista M; Framarini M; Gazzotti F; Ghermandi C; Kopf B; Saponara M; Tauceri F; Vallicelli C; Verdecchia GM; Pinna AD
Int J Gynecol Cancer; 2012 Jun; 22(5):778-85. PubMed ID: 22572845
[TBL] [Abstract][Full Text] [Related]
38. Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.
Fagotti A; Petrillo M; Costantini B; Fanfani F; Gallotta V; Chiantera V; Turco LC; Bottoni C; Scambia G
Gynecol Oncol; 2014 Feb; 132(2):303-6. PubMed ID: 24378877
[TBL] [Abstract][Full Text] [Related]
39. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.
Spiliotis J; Halkia E; Lianos E; Kalantzi N; Grivas A; Efstathiou E; Giassas S
Ann Surg Oncol; 2015 May; 22(5):1570-5. PubMed ID: 25391263
[TBL] [Abstract][Full Text] [Related]
40. Paclitaxel as HIPEC-Drug after Surgical Cytoreduction for Ovarian Peritoneal Metastases: A Randomized Phase III Clinical Trial (HIPECOVA).
Villarejo Campos P; Sánchez García S; Amo-Salas M; García Santos E; López de la Manzanara C; Alberca A; Padilla-Valverde D; Redondo Calvo FJ; Martín J
Curr Oncol; 2024 Jan; 31(2):660-671. PubMed ID: 38392042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
